Vertex Pharmaceuticals IncorporatedVRTXNASDAQ
LOADING
|||
Cost of Revenue Over Time
Trending higher, above historical average, strong compound growth.
Left:
||||
Direct costs attributable to producing goods sold
Latest
$1.53B
↑ 116% above average
Average (9y)
$708.19M
Historical baseline
Range
High:$1.53B
Low:$125.54M
CAGR
+32.0%
Consistent expansion
| Period | Value | Change |
|---|---|---|
| 2024 | $1.53B | +21.3% |
| 2023 | $1.26B | +16.8% |
| 2022 | $1.08B | +19.5% |
| 2021 | $904.20M | +22.8% |
| 2020 | $736.30M | +34.4% |
| 2019 | $547.76M | +33.7% |
| 2018 | $409.54M | +48.9% |
| 2017 | $275.12M | +30.7% |
| 2016 | $210.46M | +67.6% |
| 2015 | $125.54M | - |